INTRODUCTION {#s1}
============

Dendritic cells (DC) are central to the initiation of primary immune responses. They are the most potent antigen-presenting cells capable of stimulating naïve T cells and hence they are pivotal in the generation and control of adaptive immunity serving as a link between the innate and adaptive immune system \[[@R1]\]. DC can be subdivided into myeloid (mDC) and plasmacytoid (pDC). mDC capture antigens in the periphery and then migrate to the lymphoid organs to initiate immunity, whereas pDC are found in the thymic medulla and lymph node T cell areas and contribute to anti-viral responses \[[@R2]\].

Few studies have characterised DC in children usually with contradictory results \[[@R3]-[@R6]\]. However, studies examining different DC subsets showed that numbers of circulating pDC (but not mDC) are inversely correlated with age \[[@R6]-[@R8]\] while the phenotype and antigen presenting capacity of circulating and monocyte-derived DC is not affected with age \[[@R9]\]. Nevertheless, a recent study has described specific changes in the activation of the AKT kinase pathway resulted in an impaired migration capacity, decreased ability to uptake and process antigens and increased cytokine production by mDC in aged subjects \[[@R10]-[@R12]\]. Therefore, given the lack of studies addressing age-related effect on DC properties, here we have characterized blood and colonic DC in healthy children and adults to investigate age-related changes.

RESULTS {#s2}
=======

Characterization of human blood and colonic DC {#s2_1}
----------------------------------------------

Total DC were identified within single viable PBMC (based on the forward/side scatter properties of the cells) that were HLA-DR^+^lineage (CD3, CD14, CD16, CD19, CD34)^−^ as previously described \[[@R13], [@R14]\]. DC were subsequently divided into mDC (CD11c^+^CD123^−^) and pDC (CD11c^−^CD123^+^) (Figure [1A](#F1){ref-type="fig"}).

![Blood and colonic DC identification\
**A.** Forward and side scatter plot of peripheral blood mononuclear cells (PBMC) and subsequent doublet discrimination. Blood dendritic cells (DC) were identified as HLA-DR^+^lineage^−^ (CD3,CD14,CD16,CD19,CD34) and further divided into myeloid (CD11c^+^,mDC) and plasmacytoid (CD123^+^,pDC). **B.** Percentage and absolute numbers of mDC and **C.** pDC were correlated with the age of the donors. **D**. Colonic DC were identified with singlet viable lamina propria mononuclear cells (LPMC) based on the forward and side scatter properties of the cells and identified within CD45^+^ cells as HLA-DR^+^lineage^−^CD11c^+^. **E**. Percentage of colonic DC (referred to total LPMC) were also correlated with the age of the donor. Pearson\'s correlation analysis and *p*-value is displayed. *P*\<0.05 was considered as statistically significant.](oncotarget-07-11913-g001){#F1}

The proportion (relative to total PBMC) and absolute numbers of mDC were not affected by the age of the donor (Figure [1B](#F1){ref-type="fig"}). However, both proportion (*r* = 0.93, *p* \< 0.0001) and absolute numbers (*r* = 0.97, *p* \< 0.0001) of pDC decreased with age (Figure [1C](#F1){ref-type="fig"}).

Colonic DC were identified within single viable LPMC (based on the forward/side scatter properties of the cells) as leukocytes (CD45^+^) which were HLA-DR^+^lineage^−^. Only CD11c^+^ mDC were identified within colonic DC (Figure [1D](#F1){ref-type="fig"}) and their frequency was not affected by the age of the donor (Figure [1E](#F1){ref-type="fig"}).

BDCA2 (CD303) is absent on blood pDC in pre pubertal children {#s2_2}
-------------------------------------------------------------

Having confirmed that blood pDC levels were affected by age (Figure [1C](#F1){ref-type="fig"}), we next determined if expression of the markers typically used to identify them (i.e. CD123 and BDCA2) were also affected by the age of the donor. The expression of CD123 was unaffected by the age (Figure [2A](#F2){ref-type="fig"}) when determined as the mean fluorescence index (MFI, *r* = −0.20, *p* = 0.52) (Figure [2B](#F2){ref-type="fig"}). However, BDCA2 expression was absent on CD11c^−^CD123^+^ pDC from pre pubertal pediatric patients (Figure [2A](#F2){ref-type="fig"}) with its expression displaying a positive correlation (*r* = 0.71, *p* = 0.009) with the age of the donor (Figure [2B](#F2){ref-type="fig"}).

![BDCA2 is absent on pediatric blood pDC\
**A.** Blood myeloid (mDC) and plasmacytoid (pDC) dendritic cells were identified as in Figure [1A](#F1){ref-type="fig"} and backgated for the analysis of BDCA2 (CD303) in a 12 year old, a 15 year old and a 42 year old adult healthy control. Pooled data is shown in **B.** Pearson\'s correlation analysis and *p*-value is displayed. *P* \< 0.05 was considered as statistically significant.](oncotarget-07-11913-g002){#F2}

Blood DC immunophenotyping {#s2_3}
--------------------------

Since both circulating pDC numbers and their BDCA2 expression are influenced by the age of the donor, we next characterised DC phenotype in both healthy adults and children to identify other potential markers which may be age-influenced. Blood mDC and pDC were thus characterized for the expression of the mucosal (Integrin beta-7; β7), skin (Cutaneous lymphocyte antigen; CLA), lymph-node (C-C chemokine receptor; CCR7) and small bowel (C-C chemokine receptor 9; CCR9) homing markers, together with their activation status (CD40 and CD86) and expression of pattern recognition receptors (Toll-like receptors (TLR)2 and 4) (Figure [3](#F3){ref-type="fig"}). Blood mDC (Figure [3A and 3B](#F3){ref-type="fig"}) and pDC (Figure [3C and 3D](#F3){ref-type="fig"}) from the adult population were more mature (higher CD40 and CD86 expression) with higher small bowel homing capacity (CCR9). Additionally, adult pDC had lower lymph-node homing capacity (lower expression of CCR7) and higher potential capacity to recognize microbial antigens (higher levels of TLR2) (Figure [3C and 3D](#F3){ref-type="fig"}).

![Blood DC changes with the age\
**A.** Blood myeloid dendritic cells (mDC) were identified as in Figure [1A](#F1){ref-type="fig"} and characterized for the expression of several markers in a representative healthy children and a healthy adult. Pooled data and correlation with the age of the donor is shown in **B. C.** Blood plasmacytoid dendritic cells (pDC) were also identified as in Figure [1A](#F1){ref-type="fig"} and characterized for the expression of several markers in a representative healthy children and a healthy adult. Pooled data and correlation with the age of the donor is shown in **D.** In all cases, the expression of each individual marker is shown as percentage (%). Pearson\'s correlation analysis and *p*-value is displayed. *P* \< 0.05 was considered as statistically significant.](oncotarget-07-11913-g003){#F3}

Colonic DC characterization {#s2_4}
---------------------------

We next studied whether the age-related properties of circulating DC were also reflected in other tissues so human colonic DC were also characterized. In agreement with observations of blood mDC and pDC, colonic DC from the same donors were more mature (CD40 and CD86) in the adult population (Figure [4A and 4B](#F4){ref-type="fig"}) confirming a lower activation status of circulating and colonic DC in the pediatric population.

![Colonic DC changes with the age\
**A.** Colonic dendritic cells (DC) were identified as in Figure [1D](#F1){ref-type="fig"} and characterized for the expression of several markers in a representative healthy children and a healthy adult. Pooled data and correlation with the age of the donor is shown in **B.** Pearson\'s correlation analysis and *p*-value is displayed. *P* \< 0.05 was considered as statistically significant.](oncotarget-07-11913-g004){#F4}

Blood cytokines and chemokines {#s2_5}
------------------------------

Next, we studied the potential mechanisms that may account for changes in DC phenotype with aging by determining serum concentration of several cytokines and chemokines. Our results revealed that the adult population had higher serum levels of IL-4 and IL-8 coupled with lower levels of CXCL16 and GM-CSF while 36 other soluble mediators remained unchanged with age (Table [1](#T1){ref-type="table"}).

###### Cytokine levels in the plasma

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cytokines   Children\                                 Adults\                        *r*-value                                 *p*-value                 
              Cytokine concentration pg/ml              Cytokine concentration pg/ml                                                                       
  ----------- ----------------------------------------- ------------------------------ ----------------------------------------- ----------- ------------- -------------
  CCL1        12.95                                     1.44                           13.16                                     0.63        0.18          0.62

  CCL11       12.36                                     4.18                           14.28                                     3.01        0.23          0.49

  CCL15       1194                                      386.8                          2615                                      1756        0.64          0.12

  CCL17       13.45                                     6.21                           12.69                                     13.34       −0.15         0.76

  CCL19       10.44                                     4.66                           11.36                                     9.60        0.08          0.84

  CCL20       2.56                                      0.43                           3.07                                      1.50        0.31          0.37

  CCL21       614.1                                     259.9                          531.4                                     290.2       −0.17         0.62

  CCL24       4.89                                      2.33                           9.63                                      6.48        0.48          0.18

  CCL25       62                                        13.99                          64.10                                     18.90       0.14          0.71

  CCL26       20.21                                     11.79                          14.31                                     6.62        −0.34         0.36

  CCL27       51.22                                     33.74                          36.75                                     20.66       −0.33         0.38

  CX3CL1      23.13                                     10.58                          18.91                                     7.01        −0.27         0.40

  CXCL1       32.24                                     13.03                          32.66                                     7.27        0.05          0.90

  CXCL12      76.88                                     29.16                          152.2                                     69.46       0.56          0.11

  CXCL13      2.19                                      0.43                           1.91                                      1.20        −0.12         0.75

  CXCL16      161.2                                     51.70                          105.2                                     22.30       ***-0.62***   ***0.05***

  CXCL2       13.83                                     4.10                           18.06                                     3.26        0.52          0.17

  CXCL5       96.4                                      31.09                          55.98                                     9.68        −0.72         0.10

  CXCL6       5.13                                      1.71                           4.13                                      0.56        −0.35         0.48

  GM-CSF      31.65                                     8.46                           9.08                                      11.95       ***-0.74***   ***0.01***

  IFN gamma   [\*\*\*](#tfn_001){ref-type="table-fn"}                                  [\*\*\*](#tfn_001){ref-type="table-fn"}                             

  IL-10       2.77                                      1.31                           2.62                                      0.62        −0.01         0.96

  IL-16       194.8                                     66.78                          174.1                                     104.8       −0.04         0.91

  IL-1Beta    0.11                                      0.08                           0.13                                      0.06        0.05          0.91

  IL-2        5.81                                      1.44                           4.76                                      0.72        −0.39         0.25

  IL-4        1.10                                      0.53                           2.91                                      1.28        ***0.79***    ***0.005***

  IL-6        4.13                                      3.79                           1.08                                      0.43        −0.56         0.09

  IL-8        1.39                                      1.05                           9.92                                      7.93        ***0.69***    ***0.01***

  IP10        5.18                                      4.26                           11.1                                      6.54        0.48          0.18

  ITAC        9.80                                      5.32                           8.79                                      6.57        −0.16         0.66

  MCP1        8.97                                      7.07                           4.85                                      1.97        −0.32         0.33

  MCP2        3.93                                      3.26                           7.18                                      4.03        0.46          0.17

  MCP3        9.46                                      1.97                           14.77                                     5.13        0.54          0.20

  MCP4        9.45                                      3.19                           18.34                                     12.25       0.41          0.30

  MDC         93.88                                     25.67                          108.5                                     35.19       0.25          0.47

  MIF         116.7                                     87.68                          46.11                                     42.62       −0.42         0.22

  MIG         32.26                                     10.75                          22.23                                     15.35       −0.42         0.24

  MIP1alpha   0.95                                      0.61                           0.61                                      0.28        −0.31         0.44

  MPIF1       28.84                                     10.37                          49.82                                     30.03       0.54          0.10

  TNF Alpha   3.44                                      1.39                           3.39                                      1.17        −0.02         0.94
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Statistically significant differences for each cytokine/chemokine after Pearson\'s correlation analysis with the age are shown in bold italics

= below detection limit, pg/ml=picograms/millilitre

Finally, we determined whether such differences in cytokine/chemokine levels correlated with age-related changes in DC phenotype (Table [2](#T2){ref-type="table"}). The lower levels of pDC with aging correlated with GM-CSF concentration and inversely correlated with IL-4 and IL-8 concentrations. BDCA2 MFI on pDC, on the contrary, displayed a positive correlation withIL-4 and IL-8 levels. CD40 on pDC and TLR2 expression on mDC correlated with IL-4 and IL-8 concentrations while CD86 correlated with IL-8 concentrations and inversely with GM-CSF levels. Changes in CCR7 expression on mDC correlated with IL-4 and IL-8 levels and inversely with GM-CSF and CXCL16 levels. CCR7 expression on pDC correlated with GM-CSF levels. CCR9 expression correlated with IL-4 and IL-8 levels. β7 and CLA did not correlate with any of the cytokine or chemokine levels. As for colonic DC, CD40 expression correlated inversely with GM-CSF. The rest of the DC phenotypic markers did not correlate with any cytokine or chemokine levels. Together the evidence suggested that the circulating levels of IL-4, IL-8 and GM-CSF are the main soluble factors influencing the age-related properties of blood and colonic DC (Table [2](#T2){ref-type="table"}).

###### Blood cytokines and chemokines correlation with DC markers

  DC numbers &markers          Cytokines                                                                                           
  ---------------------------- ------------- -------------- ------------- -------------- ------------- ------------- ------------- ------------
  Blood mDC%                   0.03          0.92           0.24          0.26           −0.35         0.31          −0.5          0.1
  Blood pDC %                  ***−0.7***    ***0.02***     ***−0.69***   ***0.01***     ***0.80***    ***0.004***   ***0.41***    ***0.23***
  Colon mDC%                   −0.14         0.68           −0.47         0.13           0.32          0.36          0.21          0.54
  Blood mDC absolute numbers   −0.3          0.29           −0.1          0.69           −0.08         0.81          0.05          0.87
  Blood pDC absolute numbers   ***−0.83***   ***0.002***    ***−0.71***   ***0.01***     ***0.65***    ***0.03***    ***0.03***    ***0.94***
  CD123 MFI pDC                0.11          0.8            −0.07         0.87           −0.04         0.9           −0.5          0.3
  BDCA2 MFI pDC                ***0.96***    ***0.0005***   ***0.87***    ***0.0009***   −0.7          0.12          −0.21         0.68
  Beta7 blood mDC              0.61          0.07           0.36          0.27           −0.07         0.83          −0.52         0.11
  Beta7 blood pDC              0.05          0.87           0.6           0.07           −0.2          0.53          0.4           0.24
  Beta7 colon mDC              0.06          0.9            −0.73         0.5            −0.67         0.14          0.2           0.73
  CLA blood mDC                0.36          0.3            0.07          0.82           0.5           0.13          −0.3          0.39
  CLA blood pDC                −0.13         0.7            −0.11         0.72           0.2           0.57          −0.02         0.95
  CLA colon mDC                0.46          0.42           0.59          0.21           −0.71         0.11          0.36          0.54
  CD40 blood mDC               0.48          0.15           0.5           0.11           −0.16         0.64          −0.09         0.78
  CD40 blood pDC               ***0.73***    ***0.01***     ***0.98***    ***0.0001***   −0.05         0.13          −0.37         0.28
  CD40 colon mDC               −0.65         0.22           −0.38         0.44           −0.79         0.05          −0.13         0.83
  CD86 blood mDC               0.26          0.45           0.55          0.07           −0.45         0.18          −0.19         0.59
  CD86 blood pDC               0.41          0.23           ***0.69***    ***0.01***     ***−0.69***   ***0.02***    −0.45         0.18
  CD86 colon mDC               −0.72         0.16           −0.35         0.49           −0.71         0.09          −0.13         0.83
  TLR2 blood mDC               ***0.72***    ***0.01***     ***0.79***    ***0.003***    −0.32         0.36          −0.15         0.66
  TLR2 blood pDC               ***0.85***    ***0.001***    ***0.81***    ***0.002***    −0.37         0.28          −0.45         0.18
  TLR2 colon mDC               −0.48         0.40           −0.45         0.36           −0.49         0.31          −0.08         0.89
  TLR4 blood mDC               −0.12         0.72           −0.15         0.64           0.33          0.34          0.59          0.07
  TLR4 blood pDC               0.19          0.58           0.38          0.23           −0.22         0.53          0.0008        0.99
  TLR4 colon mDC               −0.28         0.64           −0.39         0.43           −0.51         0.29          −0.13         0.83
  CCR7 blood mDC               ***0.65***    ***0.04***     ***0.69***    ***0.01***     ***−0.84***   ***0.001***   ***−0.63***   ***0.04***
  CCR7 blood pDC               −0.25         0.47           −0.30         0.35           ***0.68***    ***0.02***    0.57          0.08
  CCR7 colon mDC               0.28          0.63           0.07          0.89           −0.56         0.23          0.21          0.72
  CCR9 blood mDC               ***0.85***    ***0.001***    ***0.57***    ***0.06***     −0.40         0.24          −0.35         0.31
  CCR9 blood pDC               ***0.82***    ***0.003***    ***0.83***    ***0.001***    −0.36         0.29          −0.55         0.09
  CCR9 colon mDC               −0.05         0.92           0.20          0.69           −0.32         0.53          −0.38         0.51

Statistically significant differences for each DC parameter after Pearson\'s correlation analysis with IL-4, IL-8, GM-CSF and CXCL16 concentration are shown in bold italics.

DISCUSSION {#s3}
==========

Here we show that expression of BDCA2 (CD303) only appears on blood pDC at around the age of puberty. In addition, a decrease in blood pDC numbers with age coupled with general increases in maturation status of both colonic and blood pDC and mDC is also described. The findings suggest that the DC populations provide evidence both of maturation of the immune system in young children as well as supporting the view that aging in older people is a process of general deterioration of immunity; development of an on-going low-grade inflammation may be an underlying cause of mortality and age-related diseases \[[@R15]\].

BDCA2 is commonly used as a pDC marker so that its absence in pre-pubertal children might lead to practical problems of pDC identification in the pediatric populations when using this marker instead of CD123. However, functional changes related to lack of BDCA2 may be more significant; BDCA2 signalling leads to reduced levels of transcripts for type-1 interferon genes \[[@R16]\] suggesting that production of such cytokines could be increased in pDC during childhood. Therefore, the lack of BDCA2 on pDC during childhood could have beneficial effects given that children have high propensity for viral infections so need this enhanced ability to make innate IFN due to lack of T cell memory. However, these potential functional differences between adult and pediatric pDC warrant further study which are limited by ethical considerations when studying healthy children. The mechanisms responsible for aging-related chronic inflammation are also not well understood. Here, we provide some bases for deteriorating immunity by describing a specific reduction of circulating pDC with age coupled with an increased maturation status of both blood and colonic DC.

Blood pDC numbers decreased with age suggesting a partial dysregulation of circulating DC. There was also an increased expression of TLR2 on pDC and increased expression of CD40 and CD86 in both mDC and pDC suggesting an increase in the general activation profile of DC with aging. Reports on young and aged adults have not shown similar increases in activation profile \[[@R17]\]. However, there was no comparison of DC in children and adults which was the focus of our study. There is reduced expression of TLR1,3,7,8 in aged individuals when compared with young adults \[[@R18], [@R19]\] and increased production of pro-inflammatory cytokines (IL-6 and IL-18) and lower amounts of anti-inflammatory mediators including IL-10 with aging in adults \[[@R17], [@R20], [@R21]\]. The studies in the literature thus support our findings that aging does result in a more pro-inflammatory DC profile. In addition,, the increased maturation status of DC was not restricted to blood pDC but was also found on blood mDC and colonic DC which suggests a more systemic activation in both blood and tissues.

In order to gain insights into possible mechanism at play in the development of DC changes with age we studied serum levels of 40 cytokines/chemokines. IL-4 and IL-8 displayed a positive correlation with aging as opposed to CXCL16 and GM-CSF which displayed a negative correlation. The increase of IL-4 and IL-8 with age is in keeping with previously published literature \[[@R17], [@R22]\] suggesting that the general body milieu becomes more pro-inflammatory with age. Indeed, IL-4 and IL-8 were the cytokines which displayed the biggest correlation with the age of the donor (Table [1](#T1){ref-type="table"}) and correlated with most of the age-induced changes of DC properties (Table [2](#T2){ref-type="table"}) including the lower numbers of circulating pDC with aging and the lack of BDCA2 expression of pre-pubertal circulating pDC suggesting they are the main cytokines influencing the age-related changes displayed by DC. However, adult mDC and pDC from healthy adult volunteers (mean age 38.7±4.2 years) did not alter the expression of any of the studied markers following short term *in vitro* stimulation with IL-4, IL-8 or GM-CSF (data not shown) suggesting that such changes may be initiated at a younger stage or require more persistent exposure.

In contrast to IL-4 and IL-8, which displayed a positive correlation with age, GM-CSF showed a negative correlation with age. GM-CSF is used to promote monocyte differentiation *in vitro* into monocyte-derived DC (MoDC) \[[@R23]-[@R26]\]. Given that lower pDC numbers with aging also correlated with lower levels of GM-CSF, GM-CSF might affect circulating pDC levels. Finally, CXCL16 was significantly higher in children. CXCL16 is an age and organ-dependent chemokine regulated by microbial exposure during early life \[[@R27]\]; lower levels of bacterial exposure during early life correlate with higher levels of CXCL16 \[[@R28], [@R29]\]. The high CXCL16 in children might be in keeping with increased antibiotic exposure of children in the current era. However the age-related changes on CXCL16 were borderline (Table [1](#T1){ref-type="table"}) so we cannot conclude that there is a direct influence.

In summary, we have described age-related changes to blood and colonic DC numbers and phenotype, particularly acquisition of the marker BDCA-2 and reduced numbers of circulating pDC with age. It will be important to determine how these changes in DC phenotype affect their function during our lifetime. The results showing lower BDCA2 on pDC in children could also be a basis for age-related functional differences in responsiveness to interferons in children.

MATERIALS AND METHODS {#s4}
=====================

Blood and colonic tissue samples {#s4_1}
--------------------------------

Blood samples and distal colonic biopsies were obtained from 8 children (age range 6-15 years, 6 males) while undergoing colonoscopy for painless rectal bleeding for suspected benign polyp. The endoscopies were macroscopically and histologically normal apart from 3 patients showing isolated rectal polyps. All the children were recruited over a 2 year period in a pediatric gastroenterology department at Chelsea & Westminster Hospital (London, UK).

Blood and distal colonic biopsies were also obtained form 10 adults (Age range 19- 52 years, 4 males) when undergoing endoscopy for change in bowel habit from an adult gastroenterology centre at St Mark\'s Hospital (London, UK). The endoscopies were macroscopically and histologically normal in all the 10 patients.

Informed consent was obtained from all patients/parents/legal guardians and the protocol was approved by the National Research ethics committee and the local research and development committee. The exclusion criteria were: diagnosed or suspected chromosomal abnormality, major medical illness or immunocompromised states.

Blood dendritic cells {#s4_2}
---------------------

Serum samples were immediately frozen at −80°C following blood extraction. Peripheral blood mononuclear cells (PBMC) were subsequently obtained by centrifugation of 10 ml of human peripheral blood over Ficoll Paque Plus (GE Healthcare, UK) at 800g, for 30 minutes at room temperature and harvesting the buffy coat layer from the interface. The PBMC were washed twice (centrifugation 650g, 10 minutes and 450g, 5 minutes) in RPMI 1640 Dutch modification (Sigma-Aldrich, Dorset, England).

Colonic biopsies {#s4_3}
----------------

Five colonic mucosal biopsy specimens from the distal colon were taken per patient. Biopsy specimens were collected in ice-chilled complete medium (RPMI 1640 Dutch modification supplemented with 10% fetal calf serum, 2mM L-glutamine, 25 μg/mL gentamicin and 100 U/mL penicillin/streptomycin) and processed within an hour. Mucus and faeces were removed from the biopsies using 1 mmol/L dithiothreitol (Sigma-Aldrich) in Hank\'s balanced salt solution (Gibco BRL, Paisley, Scotland) for 20 minutes in T25 flasks. The epithelium was removed using two 30-minute treatments with 1 mmol/L EDTA in calcium- and magnesium-free Hank\'s balanced salt solution at 37°C with gentle agitation. The biopsy specimens were cultured (1 biopsy per well in 1ml of complete medium) in a CO~2~ incubator (BioHit- 37°c, 5% CO~2~, high humidity) for 24 hours as previously described (14). Lamina propria mononuclear cells (LPMC) released from the tissue samples were passed through a 100μm cell strainer and washed twice with complete medium (Centrifugation at 600g, 5 minutes).

Antibody labelling and flow cytometry {#s4_4}
-------------------------------------

A minimum of 100,000 PBMC or LPMC were washed in fluorescence activated cell sorter (FACS) buffer (phosphate buffered saline (PBS) with 1 mmol/L EDTA and 0.02% sodium azide) and labelled on ice for 20 minutes with monoclonal antibodies at predetermined optimal concentrations. Details of the specific antibodies (including clone and conjugated fluorochromes) can be found in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Cells were then washed twice (450g, 5minutes) in FACS buffer and subsequently fixed with 1% paraformaldehyde (1% PFA). Cells were acquired within 48 hours on a FACS Canto-II flow cytometer (Becton-Dickinson, UK). Data analysis was carried out using Winlist™ software (Verity Software House, Maine, USA). The proportion of cells expressing any given surface marker of interest was determined by comparing fluorescence to that of an isotype-matched control antibody. Flow-count fluorospheres™ (Beckman Coulter, UK) were also added to all samples to determine absolute numbers.

Cytokine analysis {#s4_5}
-----------------

Cytokine and chemokine levels of 40 different metabolites were determined in the serum samples using the multiplex immunoassay Bio-Plex Pro TM Human chemokine panel (BIO-RAD) on a Luminex MAGPIX system (Merck Millipore). Determined cytokines and their detection limits (following manufacturer\'s instructions) are detailed in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

Statistical analysis {#s4_6}
--------------------

Statistical analyses were carried out using GraphPad software (La Jolla-CA, USA). Pooled data are expressed as mean values +/− SEM. Non parametric tests (Mann Whitney Rank-sum tests and Pearson\'s correlation analysis) were used and *p* \< 0.05 was considered significant.

SUPPLEMENTARY MATERIAL TABLES {#s5}
=============================

**CONFLICTS OF INTEREST**

None.

**GRANT SUPPORT**

The authors gratefully acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC). This research was funded by the BBSRC Institute Strategic Programme for Gut Health and Food Safety BB/J004529/1. The authors also gratefully acknowledge the support of the Westminster Medical School Research Trust and Crohn\'s in Childhood Research Association (Reference JRC SG 002 03/13-14)
